Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Low Testosterone (May 2020)

Posted by Matt Breese on May 22, 2020

Find me on:

According to our recent payer coverage analysis for low testosterone treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for low testosterone treatments shows that under the pharmacy benefit, about 58% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Low Testosterone-2Q2020Data snapshot as of Q2 2020

Trends: In February 2020, Clarus Therapeutics, Inc. said that its Jatenzo (testosterone undecanoate) is available by prescription in the U.S. In March 2019, the FDA approved the medication for the treatment of males with low testosterone levels because of specific genetic disorders or pituitary glanddamaging tumors.  

To read the full Reality Check on Low Testosterone treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing